Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Rigrodsky & Long, P.A. Announces Investigation Of BioClinica, Inc. Buyout



  Rigrodsky & Long, P.A. Announces Investigation Of BioClinica, Inc. Buyout

Business Wire

WILMINGTON, Del. -- January 31, 2013

Rigrodsky & Long, P.A.:

  * Do you own shares of BioClinica, Inc. (NASDAQ GM: BIOC)?
  * Did you purchase any of your shares prior to January 30, 2013?
  * Do you think the proposed buyout price is too low?
  * Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal
claims against the board of directors of BioClinica, Inc. (“BioClinica” or the
“Company”) (NASDAQ GM: BIOC) regarding possible breaches of fiduciary duties
and other violations of law related to the Company’s entry into an agreement
to be acquired by JLL Partners, Inc. (“JLL”) in a transaction valued at
approximately $123 million.

Click here to learn more:
http://www.rigrodskylong.com/investigations/bioclinica-inc-bioc.

Under the terms of the proposal, public shareholders of BioClinica will
receive $7.25 per share in cash for each share of BioClinica they own.

The investigation concerns whether BioClinica’s board of directors failed to
adequately shop the Company and obtain the best possible value for
BioClinica’s shareholders before entering into an agreement with JLL.
According to Yahoo! Finance, at least one analyst has set a price target for
BioClinica stock at $9.00.

If you own the common stock of BioClinica and purchased your shares before
January 30, 2013, if you have information or would like to learn more about
these claims, or if you wish to discuss these matters or have any questions
concerning this announcement or your rights or interests with respect to these
matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate
Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242,
by e-mail to info@rigrodskylong.com, or at:
http://www.rigrodskylong.com/investigations/bioclinica-inc-bioc.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City,
New York, regularly prosecutes securities class, derivative and direct
actions, shareholder rights litigation and corporate governance litigation, on
behalf of shareholders in states and federal courts throughout the United
States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:

Rigrodsky & Long, P.A.
Peter Allocco
(888) 969-4242
(516) 683-3516
Fax: (302) 654-7530
info@rigrodskylong.com
http://www.rigrodskylong.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement